Microfluidic lipid nanoparticles co-delivering siMOB1A and paclitaxel for ovarian cancer therapy.
7 affiliations
- 1Department of Obstetrics and Gynecology, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, People's Republic of China.
- 2Department of Radiation Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
- 3Xiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, People's Republic of China.
- 4Department of Obstetrics and Gynecology, Quan Zhou Women's and Children's Hospital, Quanzhou, People's Republic of China.
- 5Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, People's Republic of China.
- 6Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, People's Republic of China. [email protected].
- 7Department of Obstetrics and Gynecology, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, People's Republic of China. [email protected].
Abstract
Background
Ovarian cancer is the foremost cause of mortality among gynecologic malignancies. Paclitaxel (PTX) exerts a significant therapeutic effect on ovarian cancer by targeting microtubules and impeding the cell cycle progression during the mitosis phase. MOB kinase activator 1 A (MOB1A) has been proven to regulate the cycle progression of ovarian cancer cells. Utilizing small interfering RNA (siRNA) to target MOB1A (siMOB1A) displays efficiency in blocking the cycle progression during the interphase of mitosis. The combined application of paclitaxel and siMOB1A holds promise in halting the cell cycle progression in ovarian cancer cells across different phases.Methods
Lipid nanoparticles delivering siMOB1A and paclitaxel (SPLNPs) were prepared by microfluidic technology. Then, the size distribution, zeta potential, morphology, and size stability of SPLNPs were characterized. Confocal laser scanning microscopy and flow cytometry were used to detect the cellular uptake ability of SPLNPs. RT-qPCR and Western blot were performed to evaluate the knockdown effect on MOB1A mRNA and protein levels. CCK-8 and colony formation assay were performed to evaluate the cytotoxicity of SPLNPs. A wound-healing assay was performed to detect the effect on cell migration. Flow cytometry was used to assess the effects on the cell cycle and apoptosis. Tumor-bearing mouse models were constructed to detect the distribution, anti-tumor effect, and biosafety in vivo.Results
SPLNPs exhibited spherical morphology with an average diameter of approximately 113.5 nm and were efficiently internalized by ovarian cancer cells. The drug loading content was 7.50% for siMOB1A and 2.07% for paclitaxel. Through the RNA interference (RNAi) mechanisms facilitated by SPLNPs, effective suppression of MOB1A expression in ovarian cancer was achieved at both mRNA and protein levels. The knockdown efficiency reached 66.2% at the siMOB1A dose of 5 nM. Then, enhanced apoptosis of ovarian cancer cells was observed, accompanied by cell cycle modulation. Compared to siMOB1A and paclitaxel, SPLNPs showed superior cytotoxicity and effectively curbed the migration and proliferation ability of ovarian cancer cells. Additionally, in vivo experiments demonstrated that SPLNPs inhibit tumor growth, achieving an inhibition rate of approximately 65.23%.Conclusions
SPLNPs enabled the co-delivery of siMOB1A and PTX, resulting in enhanced antitumor activity and providing a promising co-delivery platform for ovarian cancer therapy.
Related
- Engineered SHED-EVs delivering FtMt siRNA rescue mitophagy and bone formation in smoking-related osteoporosis
- Engineering the paclitaxel biosynthetic pathway in Physcomitrium patens for de novo and stable biosynthesis
- Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke
- Molecular Mechanisms and Signaling Pathways Underlying the Synergistic Effect of Metformin and Paclitaxel in Preclinical Cancer Models: A Systematic Review.
- Butyrate Triggers Neuronal Signaling via Release of Colonic Serotonin in a Microfluidic Model of Gut-Brain Axis
BibTeX
@article{xu2026microfluidic,
title = {{Microfluidic lipid nanoparticles co-delivering siMOB1A and paclitaxel for ovarian cancer therapy.}},
author = {Jing-Ying Xu and Ke Liu and Li-Ying Chen and Chen Liu and Deng-Yue Chen and San-Gang Wu and Juan Zhou},
journal = {Journal of ovarian research},
year = {2026},
month = jul,
doi = {10.1186/s13048-026-02215-6},
url = {https://europepmc.org/article/MED/42972402},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Microfluidic lipid nanoparticles co-delivering siMOB1A and paclitaxel for ovarian cancer therapy.
AU - Jing-Ying Xu
AU - Ke Liu
AU - Li-Ying Chen
AU - Chen Liu
AU - Deng-Yue Chen
AU - San-Gang Wu
AU - Juan Zhou
PY - 2026
DA - 2026/07/31
JO - Journal of ovarian research
DO - 10.1186/s13048-026-02215-6
UR - https://europepmc.org/article/MED/42972402
AB - Background Ovarian cancer is the foremost cause of mortality among gynecologic malignancies. Paclitaxel (PTX) exerts a significant therapeutic effect on ovarian cancer by targeting microtubules and impeding the cell cycle progression during the mitosis phase. MOB kinase activator 1 A (MOB1A) has been proven to regulate the cycle progression of ovarian cancer cells. Utilizing small interfering RNA (siRNA) to target MOB1A (siMOB1A) displays efficiency in blocking the cycle progression during the interphase of mitosis. The combined application of paclitaxel and siMOB1A holds promise in halting the cell cycle progression in ovarian cancer cells across different phases.Methods Lipid nanoparticles delivering siMOB1A and paclitaxel (SPLNPs) were prepared by microfluidic technology. Then, the size distribution, zeta potential, morphology, and size stability of SPLNPs were characterized. Confocal laser scanning microscopy and flow cytometry were used to detect the cellular uptake ability of SPLNPs. RT-qPCR and Western blot were performed to evaluate the knockdown effect on MOB1A mRNA and protein levels. CCK-8 and colony formation assay were performed to evaluate the cytotoxicity of SPLNPs. A wound-healing assay was performed to detect the effect on cell migration. Flow cytometry was used to assess the effects on the cell cycle and apoptosis. Tumor-bearing mouse models were constructed to detect the distribution, anti-tumor effect, and biosafety in vivo.Results SPLNPs exhibited spherical morphology with an average diameter of approximately 113.5 nm and were efficiently internalized by ovarian cancer cells. The drug loading content was 7.50% for siMOB1A and 2.07% for paclitaxel. Through the RNA interference (RNAi) mechanisms facilitated by SPLNPs, effective suppression of MOB1A expression in ovarian cancer was achieved at both mRNA and protein levels. The knockdown efficiency reached 66.2% at the siMOB1A dose of 5 nM. Then, enhanced apoptosis of ovarian cancer cells was observed, accompanied by cell cycle modulation. Compared to siMOB1A and paclitaxel, SPLNPs showed superior cytotoxicity and effectively curbed the migration and proliferation ability of ovarian cancer cells. Additionally, in vivo experiments demonstrated that SPLNPs inhibit tumor growth, achieving an inhibition rate of approximately 65.23%.Conclusions SPLNPs enabled the co-delivery of siMOB1A and PTX, resulting in enhanced antitumor activity and providing a promising co-delivery platform for ovarian cancer therapy.
SN - 1757-2215
ER -